Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks From the Dupilumab Italian Prurigo Nodularis Study

    Marina Talamonti, Edoardo Mortato, Alessandra Narcisi … Marco Galluzzo
    Studysummary This study found that treating moderate-to-severe prurigo nodularis with dupilumab significantly improved itch severity, skin condition, and quality of life over 104 weeks, with a favorable safety profile, even in elderly and comorbid patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →